SAN FRANCISCO--(BUSINESS WIRE)--Aug. 25, 2015--
Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an
animal health company focused on developing and commercializing
first-in-class gastrointestinal products for companion and production
animals, announced today that Lisa Conte, Jaguar’s President and CEO,
and John Kallassy, Chief Financial and Operating Officer, will be
attending the 2015 KC Animal Health Investment Forum at the Kansas City
Convention Center on Tuesday, September 1.
The KC Animal Health Investment Forum showcases animal health and
nutrition companies from around the world. It provides a unique
opportunity for emerging companies to introduce new technologies to
investment firms, venture capital funds and other animal health
companies. The Forum offers one of the only opportunities for companies
in the animal health sector to present their vision and business plan to
potential investors. Past presenting companies have gained increased
exposure within the investment community and animal health industry, in
many cases directly resulting in new licensing agreements and
distribution contracts.
Jaguar management will be available for one-on-one meetings during the
conference. To schedule a meeting, please contact KCSA Strategic
Communications at jaguar@kcsa.com.
About Jaguar Animal Health, Inc.
Jaguar Animal Health, Inc. is an animal health company focused on
developing and commercializing first-in-class gastrointestinal products
for companion and production animals. Canalevia™ is Jaguar’s
lead prescription drug product candidate for the treatment of various
forms of watery diarrhea in dogs. Neonorm™ Calf is the
Company’s lead non-prescription product. Canalevia is a canine-specific
formulation of crofelemer, an active pharmaceutical ingredient isolated
and purified from the Croton lechleri tree, which is sustainably
harvested. Neonorm is a standardized botanical extract derived from the Croton
lechleri tree. Canalevia and Neonorm are distinct products that act
at the same last step in a physiological pathway generally present in
mammals. Jaguar has filed nine Investigational New Animal Drug
applications, or INADs, with the FDA and intends to develop
species-specific formulations of Neonorm in six additional target
species, and formulations of Canalevia for cats, horses and dogs.
For more information, please visit www.jaguaranimalhealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150825005887/en/
Source: Jaguar Animal Health, Inc.
KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
Tram
Bui, 212-896-1290
tbui@kcsa.com
Jaguar-JAGX
